Prospective evaluations of continuous weekly paclitaxel regimen in recurrent platinum-resistant epithelial ovarian cancer

Gynecologic Oncology

Volumn 102, Issue 1, 2006, Pages 49-53

  Le, T ^a   Hopkins, L ^a   Baines, K A ^a   Rambout, L ^a   Al Hayki, M ^a   Kee Fung, M Fung ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Platinum resistant; Toxicities; Weekly paclitaxel

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; DIPHENHYDRAMINE; DOXORUBICIN; PACLITAXEL; PLATINUM; RANITIDINE; TOPOTECAN;

ADULT; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CHI SQUARE TEST; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; DEMOGRAPHY; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; EVALUATION; FEMALE; HUMAN; KAPLAN MEIER METHOD; LOW DRUG DOSE; NEUROTOXICITY; OVARY CANCER; PRIORITY JOURNAL; RADIODIAGNOSIS; RECURRENT CANCER; STATISTICAL SIGNIFICANCE; SURVIVAL TIME; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; EPITHELIAL CELLS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; PACLITAXEL; PROSPECTIVE STUDIES;

EID: 33744945789     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2005.11.025     Document Type: Article

References (27)

1. Cannistra S.A. Cancer of the ovary. N. Engl. J. Med. 329 (1993) 1550-1559
2. Hogberg T., Glimelius B., and Nygren P. A systematic overview of chemotherapy effects in ovarian cancer. Acta Oncol. 40 2-3 (2001) 340-360
3. Ghamande S., Lele S., Marchetti D., Baker T., and Odunsi K. Weekly Paclitaxel in patients with recurrent or persistent advanced ovarian cancer. Int. J. Gynecol. Cancer 13 2 (2003 (Mar-Apr)) 142-147
4. Kaern J., Baekelandt M., and Trope C.G. A phase II study of weekly Paclitaxel in platinum and Paclitaxel-resistant ovarian cancer patients. Eur. J. Gynaecol. Oncol. 23 5 (2002) 383-389
5. Kawagoe H., Kawata T., Nishio S., Shimomura T., Fujiyoshi K., Ishimatsu J., et al. Weekly Paclitaxel infusion in patients with recurrent ovarian cancer-A pilot study. Gan To Kagaku Ryoho 30 1 (2003 (Jan)) 151-154
6. Thomas H., and Rosenberg P. Role of weekly Paclitaxel in the treatment of advanced ovarian cancer. Crit. Rev. Oncol. Hematol. 44 (2002 (Dec. 27)) S43-S51 [Suppl]
7. Marchetti P., Urien S., Cappellini G.A., Ronzino G., and Ficorella C. Weekly administration of Paclitaxel: theoretical and clinical basis. Crit. Rev. Oncol. Hematol. 44 (2002 (Dec 27)) S3-S13 [Suppl]
8. Kumagai M., Fujii T., Komatsu M., Kusuda T., Takehara K., Shinkou S., et al. Paclitaxel plus carboplatin in ovarian cancer-Comparison of adverse effects between monthly and weekly administration. Gan To Kagaku Ryoho 31 4 (2004 (Apr)) 555-559
9. Markman M., Hall J., Spitz D., Weiner S., Carson L., Van Le L., et al. Phase II trial of weekly single-agent Paclitaxel in platinum/Paclitaxel-refractory ovarian cancer. J. Clin. Oncol. 20 9 (2002 (May 1)) 2365-2369
10. Takano M., Kikuchi Y., Kita T., Suzuki M., Ohwada M., Yamamoto T., et al. Phase I and pharmacological study of single Paclitaxel administered weekly for heavily pre-treated patients with epithelial ovarian cancer. Anticancer Res. 22 3 (2002 (May-Jun)) 1833-1838
11. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. J. Natl. Cancer Inst. 92 (2000) 205-216
12. Vergote I., Rustin G.J.S., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J. Natl. Cancer Inst. 92 (2000) 1534-1535
13. Le T., Leis A., Pahwa P., Wright K., Ali K., Reeder B., et al. Quality of life evaluations in patients with ovarian cancer during chemotherapy treatment. Gynecol. Oncol. 92 3 (2004 (Mar)) 839-844
14. Ledermann J.A., and Wheeler S. How should we manage patients with "platinum-sensitive" recurrent ovarian cancer?. Cancer Invest. 22 Suppl. 2 (2004) 2-10
15. Tummala M.K., and McGuire W.P. Recurrent ovarian cancer. Clin. Adv. Hematol. Oncol. 3 9 (2005 (Sep)) 723-736
16. Vasey P.A. Management of recurrent epithelial ovarian carcinoma. Aust. N. Z. J. Obstet. Gynaecol. 45 4 (2005 (Aug)) 269-277
17. Kita T., Kikuchi Y., Takano M., Suzuki M., Oowada M., Konno R., et al. The effect of single weekly Paclitaxel in heavily pretreated patients with recurrent or persistent advanced ovarian cancer. Gynecol. Oncol. 92 3 (2004 (Mar)) 813-818
18. Dunder I., Berker B., Atabekoglu C., and Bilgin T. Preliminary experience with salvage weekly paclitaxel in women with advanced recurrent ovarian carcinoma. Eur. J. Gynaecol. Oncol. 26 1 (2005) 79-82
19. Markman M., Hall J., Spitz D., Weiner S., Carson L., Van Le L., and Baker M. Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer. J. Clin. Oncol. 20 9 (2002 (May 1)) 2365-2369
20. Garcia A.A., O'Meara A., Bahador A., Facio G., Jeffers S., Kim D.Y., and Roman L. Phase II study of gemcitabine and weekly paclitaxel in recurrent platinum-resistant ovarian cancer. Gynecol. Oncol. 93 2 (2004 (May)) 493-498
21. Havrilesky L.J., Alvarez A.A., Sayer R.A., Lancaster J.M., Soper J.T., et al. Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer. Gynecol. Oncol. 88 1 (2003 (Jan)) 51-57
22. Kurihara M., Sakamoto H., Ohta Y., Takami T., Takami M., Nakayama Y., et al. Patient compliance and the quality of life are well maintained in weekly Paclitaxel and carboplatin therapy for advanced gynecologic cancers in Japanese women. Gan To Kagaku Ryoho 28 1 (2001 (Jan)) 55-61
23. Rosenberg P., Andersson H., Boman K., Ridderheim M., Sorbe B., Puistola U., et al. Randomized trial of single agent Paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncol. 41 5 (2002) 418-424
24. Pecorelli S., Odicino F., and Favalli G. Consolidation therapies revisited: weekly Paclitaxel. Int. J. Gynecol. Cancer 13 Suppl. 2 (2003 (Nov-Dec)) 208-211
25. Garcia A.A., O'Meara A., Bahador A., Facio G., Jeffers S., Kim D.Y., et al. Phase II study of gemcitabine and weekly Paclitaxel in recurrent platinum-resistant ovarian cancer. Gynecol. Oncol. 93 2 (2004 (May)) 493-498
26. Havrilesky L.J., Alvarez A.A., Sayer R.A., Lancaster J.M., Soper J.T., Berchuck A., et al. Weekly low-dose carboplatin and Paclitaxel in the treatment of recurrent ovarian and peritoneal cancer. Gynecol. Oncol. 88 1 (2003 (Jan)) 51-57
27. Sehouli J., Stengel D., Elling D., Ortmann O., Blohmer J., Riess H., et al. First-line chemotherapy with weekly Paclitaxel and carboplatin for advanced ovarian cancer: a phase I study. Gynecol. Oncol. 85 2 (2002 (May)) 321-326